Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose:

To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine.

Design:

Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment with ebastine 20mg once daily or placebo (1:1 randomization).

End points:

End point is the effect of treatment on clinical symptoms and visceral hypersensitivity which will be evaluated with a barostat test.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Katholieke Universiteit Leuven; KU Leuven
• Treatments: Ebastine; Histamine H1 Antagonists

Criteria

Inclusion Criteria:

• Irritable Bowel Syndrome (ROME III criteria)

• age 18-65 years

Exclusion Criteria:

• medication: antidepressants or H1-receptor antagonists

• pregnancy, breast feeding

• co-morbidity: severe kidney- and/or liver disease